

Major R&D Pipeline: 3 ADCs

As of April 2020




Phase 1

Phase 2

Phase 3


Submitted

Phase 1	Phase 2	Phase 3	Submitted
DS-8201(US/EU) Anti HER2-ADC BC, bladder cancer (with nivolumab)	DS-8201 (US/EU) prep Anti HER2-ADC BC, NSCLC (with pembrolizumab)	DS-8201 (EU/Asia) Anti HER2-ADC 3L BC DESTINY-Breast01	DS-8201(JP/US/EU/Asia) Anti HER2-ADC 3L BC DESTINY-Breast02
U3-1402 (JP/US) Anti HER3-ADC BC	U3-1402 (JP/US/Asia) Anti HER3-ADC EGFRm NSCLC	DS-8201 (JP/Asia) Anti HER2-ADC 3L GC DESTINY-Gastric01 	DS-8201(JP/US/EU/Asia) Anti HER2-ADC 2L BC DESTINY-Breast03
DS-1062(JP/US) Anti TROP2-ADC NSCLC		DS-8201(JP/US/EU) Anti HER2-ADC NSCLC DESTINY-Lung01	DS-8201(JP/US/EU/Asia) Anti HER2-ADC HER2 low BC DESTINY-Breast04
		DS-8201(JP/US/EU) Anti HER2-ADC CRC DESTINY-CRC01	
		DS-8201 (US/EU) Anti HER2-ADC 2L GC DESTINY-Gastric02	
		DS-8201(US/EU/Asia) prep Anti HER2-ADC NSCLC (with durvalumab) HUDSON	
		DS-8201(US/EU/Asia) prep Anti HER2-ADC TNBC(with durvalumab) BEGONIA	

DS-8201
 U3-1402
 DS-1062

BC: breast cancer, CRC: colorectal cancer, GC: gastric cancer, NSCLC: non-small cell lung cancer, TNBC: triple negative breast cancer

 project in oncology that is planned to be submitted for approval based on the results of phase 2 trials

 SAKIGAKE Designation (JP)

Major R&D Pipeline: Alpha

As of April 2020



Phase 1

Phase 2

Phase 3

Submitted

DS-3201 (JP/US)
EZH1/2 inhibitor
Non-Hodgkin's
Lymphomas (PTCL)



DS-3201 (US)
EZH1/2 inhibitor
AML, ALL

DS-1647 (G47Δ) (JP)
Oncolytic HSV-1
Malignant glioma
IIS



Quizartinib (JP/US/EU)
FLT3 Inhibitor
1L AML



Pexidartinib (EU)
CSF-1/KIT/FLT3 inhibitor
TGCT

DS-3201 (US)
EZH1/2 inhibitor
SCLC

DS-3032 (JP/US)
MDM2 Inhibitor
Solid tumors (liposarcoma)



DS-3201 (JP)
EZH1/2 inhibitor
ATL/L

Edoxaban (JP)
FXa inhibitor
Atrial fibrillation in the very
elderly

**Axicabtagene
ciloleucel/Axi-Cel (JP)**
Anti CD19 CAR-T cells
R/R B-cell lymphoma



DS-3032 (JP/US)
MDM2 Inhibitor
AML

PLX2853 (US)
BET inhibitor
AML

Prasugrel (JP)
ADP receptor inhibitor
Ischemic stroke

VN-0107/MEDI3250 (JP)
live attenuated influenza
vaccine nasal spray

DS-1001 (JP)
Mutant IDH1 inhibitor
Glioma

PLX2853 (US)
BET inhibitor
Solid tumor

Mirogabalin (JP)
α₂δ Ligands
Central neuropathic pain

DS-1205 (Asia)
AXL inhibitor
NSCLC (with osimertinib)

DS-1205 (JP)
AXL inhibitor
NSCLC (with gefitinib)

Esaxerenone (JP)
MR blocker
Diabetic nephropathy

DS-6157 (JP/US)
Anti GPR20-ADC
GIST

DS-7300 (JP/US)
Anti B7-H3-ADC
Solid Tumors

VN-0102/JVC-001 (JP)
Measles mumps rubella
combined vaccine

DS-1211 (US)
TNAP inhibitor
Pseudoxanthoma elasticum

DS-5141 (JP)
ENA oligonucleotide
DMD



DS-2741 (JP)
Anti-Orai1 antibodies
Atopic dermatitis

Oncology

Specialty medicine

Vaccine

ALL: acute lymphocytic leukemia, AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, DMD: Duchenne muscular dystrophy, GIST: gastrointestinal stromal tumor, IIS: investigator-initiated study, NSCLC: non-small cell lung cancer, PTCL: peripheral T-cell lymphoma, SCLC: small cell lung cancer, TGCT: tenosynovial giant cell tumor
: project in oncology that is planned to be submitted for approval based on the results of phase 2 trials

: SAKIGAKE Designation (JP) : Orphan drug designation (JP/US/EU)